This is in agreement with guidance for the use of TNFα antagonists in rheumatoid arthritis [11], which demonstrated an increased proportion of detailed treatment and prescribing recommendations in consensus statements, as opposed to clinical guidelines. The gene discussed is TNF; the disease is rheumatoid arthritis.